Potency Assurance
Why Potency Cannot Be Reduced to a Release Assay in Active Immunotherapy Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-16Aug 24, 2026
Cell Therapy
NueCell Bio Launches as a New Translational Partner to Accelerate Cell Therapies from Discovery into GMP Manufacturing
NueCell Bio
PR-08-26-01Aug 5, 2026
In Vivo CAR-T
Five Companies Bringing In Vivo CAR-T Therapy Closer to the Clinic
Emma Gormlie
Nice Insight
PAO-07-26-PA-13Jul 30, 2026
Stem Cells
Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-07-26-PA-11Jul 22, 2026
Pathfinder
NK Cell Therapy vs. T Cell Therapy: Which Cell Therapy Platform Is Better for Cancer Treatment?
Nice Insight
PAO-26-PF-04Apr 24, 2026
Allogeneic
Allogeneic CAR Cell Therapies: The Rise of Off-the-Shelf Immunotherapy
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-02-26-NI-15Feb 19, 2026
Cell Therapy
Kincell Bio Announces Partnership with RegCell to Advance Treg Cell Therapies into Clinical Trials for Autoimmune Diseases
Kincell Bio
PR-02-26-02Feb 11, 2026
T Cell Manufacturing
Promise vs. Practice: Adaptive Control Systems in Cell and Gene Therapy Bioreactors
David Alvaro, Ph.D.
Pharma's Almanac
PAO-02-26-NI-06Feb 9, 2026
In Vivo CAR-T
In Vivo CAR-T Arrives: Early Signals from a New Generation of Cell Therapies
David Alvaro, Ph.D.
Pharma's Almanac
PAO-12-25-NI-06Dec 10, 2025
mRNA Therapeutics
mRNA Therapeutics Are Just Getting Started: Charting a Post-Pandemic Path Forward
Jan Bekker; Phillip Elliott, Ph.D.; Jason Arcediano
BioCina
PAO-10-25-CL-08Nov 10, 2025
CAR-T Cell Therapies
CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B
Carsgen Therapeutics
PR-11-25-NI-02Nov 3, 2025
Cell Therapy
Building a Better Cell Therapy CDMO
Kincell Bio
PAO-08-25-BIO-04Sep 5, 2025
Cell Therapy
How Kincell Bio is Supporting Tomorrow's Cell Therapy Innovators
Mark Bamforth
Kincell Bio
PAO-08-25-BIO-03Aug 22, 2025
In VIvo CAR-T
In Vivo CAR-T Technology Poised to Expand Access and Indications
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-08-25-NI-07Aug 11, 2025
LOGIC GATES
Boolean Biology: The Future of Logic-Gated Cell and Gene Therapies
David Alvaro, Ph.D.
Pharma's Almanac
PAO-03-25-NI-03Mar 14, 2025
Immuno-oncology
Immuno-Oncology at the Forefront of Cancer Medicine
David Alvaro, Ph.D.
Pharma's Almanac
PAO-25-30-10Mar 2, 2025
Approval
Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences
PR-02-25-NI-16Feb 19, 2025
Clinical Trials
EXUMA Biotech Announces Phase 1 Results for its Autologous HER2 Directed CAR-T Product at ASCO GI 2025
EXUMA Biotechnology
PR-01-25-NI-26Feb 11, 2025
Clinical Trials
CARsgen's First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T Trial Achieves sCR at Week 4
Carsgen Therapeutics
PR-02-25-NI-09Feb 10, 2025
Cell Therapy
From Research to Clinical Trials to Commercialization: Advancing CGT with Frozen Cellular Starting Materials
Dominic Mancini
OrganaBio
PAO-01-25-CL-13Jan 28, 2025